Lawyer Welcomes Alzheimer’s Drug Recommendations

Draft Guidelines Backed By Expert

08.10.2010


A proposal which has suggested that more people should be allowed access Alzheimer’s drugs has been welcomed by a lawyer at Irwin Mitchell.

Mathieu Culverhouse, who specialises in cases related to healthcare, comment after the National Institute of Health and Clinical Excellence released new draft guidelines suggesting that those in mild stages should be able to get hold of Aricept (donepezil), Reminyl (galantamine) and Exelon (rivastigmine).

In addition, Ebixa (memantine), which was only previously available to patients through clinical trials, should be an option for those with severe cases.

Discussing the recommendations, Mathieu Culverhouse said it is vital that people gain access to the most suitable treatments.

“I welcome the announcement that authorities are looking closer at the issue of making Alzheimer’s drugs more widely available,” he outlined.

“If such plans are given the green light, thousands of people will reap the benefits of what these treatments can offer them in terms of a future. I hope serious consideration is paid to making these drugs available and that everyone who should benefit can.”